Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin Dose

Recruiting now · Not applicable

Conditions studied: Type 1 Diabetes Mellitus

In brief

People living with type 1 diabetes (PwT1D) are recommended to administer insulin 10-15 minutes before meal consumption (pre-bolus), to account for the delay in the glucose lowering action associated with subcutaneously administered insulin. Due to the demands of day-to-day life, pre-bolusing is not always possible or may be forgotten. With continuous glucose monitors (CGMs), PwT1D may be alerted to this missed insulin dose by a CGM alert, including rapidly rising glucose (change \>2.5mmol/L/15min) or hyperglycemia (\>10.0 mmol/L), and deliver a mistimed (post-prandial) dose in response to CGM alert. This study was designed to determine the effect of combining a post-prandial/mistimed insulin dose with 15 minutes of brisk walking. It is expected that walking will help to minimize or prevent hyperglycemia after a mistimed bolus insulin dose, as well as blunt the rise in glucose following a mistimed insulin dose.

Key facts

Study ID

NCT06686329

Run by

Jane Yardley

People needed

30

Starts

2025-03-17

Expected to finish

2026-09-30

Last updated by the study team

2026-03-12

Who can join

Age: 18 and older, up to 24. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 18-24 years
• Type 1 diabetes diagnostic for at least two years
• Estimated glycated hemoglobin or glucose management indicator obtained from the past 30 days of CGM data of < 9.9%
• Use a Dexcom G7 CGM in routine care

You may not qualify if…

• Changes in insulin management strategy within the past 2 months
• Diagnosis of gastroparesis
• Having a condition that could render exercise harmful
• Intolerance to gluten and lactose
• Having significant renal disease (e.g., eGRF < 30 ml/min)
• Inability to provide informed consent due to cognitive deficit
• Currently taking other medications (other than insulin) that may alter glucose metabolism (e.g., non-insulin antihyperglycemic drugs such as sglt2-inhibitors, corticosteroids), unless dosages thereof have been stable for more than three months
• For women, being pregnant or breastfeeding

Where it is running

• Institut de recherches cliniques de Montréal — Montreal, Quebec, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.